Transdermal therapeutic system comprising as active component buprenorphine
AssigneeLTS Lohmann Therapie-Systeme AG
InventorsThomas Hille, Lothar Deurer, Hans-Rainer Hoffmann
Life of this patent
Estimating the term…
Abstract
The controlled release of buprenorphine or the pharmaceutically acceptable salts thereof to the skin over a period of time of at least 24 hours is ensured by a transdermal therapeutic system consisting of a backing layer which is impermeable to the active substance, a pressure-sensitive adhesive reservoir layer, and optionally a removable protective layer. Said reservoir layer of said system comprises 20 to 90%-wt polymeric material, 0.1 to 30%-wt softener, 0.1 to 20%-wt buprenorphine base or one of the pharmaceutically acceptable salts thereof, and 0.1 to 30%-wt solvent for the active substance base.
Claims18
A transdermal therapuetic system for the administration of buprenorphine to the skin comprising a backing layer which is impermeable to the active substance, a pressure-sensitive adhesive reservoir layer, and optionally a removable protective layer, the reservoir layer by weight comprising 20 to 90% of a polymeric matrix, 0.1 to 30% of a softening agent, 0.1 to 20% of buprenorphine base or of a pharmaceutically acceptable salt thereof and 0.1 to 30% of a solvent for the buprenorphine or salt thereof.
A laminated composite for administering buprenorphine or a pharmaceutically acceptable salt thereof to an individual transdermally comprising
- (a) a polymer backing layer that is substantially impermeable to buprenorphine or the pharmaceutically acceptable salt thereof;
- and
- (b) a reservoir layer comprising an acrylate pressure-sensitive adhesive, 0.1 to 20% of buprenorphine base or of a pharmaceutically acceptable salt thereof, 0.1 to 30% of an ester of a carboxylic acid acting as a softening agent and 0.1 to 30% of a solvent for buprenorphine having at least one acidic group.
A liminated composite for administering buprenorphine or a pharmaceutically acceptable salt thereof to an individual transdermally comprising
- (a) a polymer backing layer that is substantially impermeable to buprenorphine or the pharmaceutically acceptable salt thereof;
- and
- (b) a reservoir layer comprising an acrylate pressure-sensitive adhesive, 0.1 to 20% of buprenorphine base or of a pharmaceutically acceptable salt thereof, 0.1 to 30% of an ester of a carboxylic acid acting as a softening agent and 0.1 to 30% of a solvent for buprenorphine having at least one acidic group, wherein the skin contact area of the composite is 16 cm.sup.2 and the rate of administration from the composite is about 40 .mu.g/hr.
Dependencies are inferred from the claim text.